Decitabine
From Wikipedia, the free encyclopedia
 |
|
|
Decitabine
|
|
| Systematic (IUPAC) name | |
| 4-amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)- 1,3,5-triazin-2(1H)-one |
|
| Identifiers | |
| CAS number | |
| ATC code | L01 |
| PubChem | |
| Chemical data | |
| Formula | C8H12N4O4 |
| Mol. mass | 228.0859 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | <1% |
| Metabolism | ? |
| Half life | 30 minutes |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
D |
| Legal status | |
| Routes | Intravenous |
Decitabine (trade name Dacogen), or 5-aza-2'-deoxycytidine, is indicated for treatment of patients with myelodysplastic syndrome (MDS), including previously treated and untreated, de novo, and secondary MDS of all FAB subtypes and Intermediate-1, Intermediate-2, and High-Risk IPSS groups. It functions in the same way as 5-Azacytidine.
[edit] Clinical uses
Decitabine is indicated for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups.
